KR20230105518A - Composition for the treatment of autoimmune diseases and mitochondria using theragnostic gold nanomedical particles - Google Patents

Abstract

The present invention relates to a composition for treating autoimmune diseases and mitochondria using theragnostic gold nanomedical particles. was confirmed to protect. In addition, it was confirmed that mitochondrial activity, which is known to be decreased in the rheumatoid arthritis model, was increased, and expression of Th17 cells was suppressed. In addition, it was confirmed that the amounts of inflammatory cytokines IL-1β, IL-17, IL-6, and TNF-α were reduced, and the amount of citrulinet vimentin specific IgG in serum was reduced, thereby confirming the therapeutic effect of arthritis.

Description

Composition for the treatment of autoimmune diseases and mitochondria using theragnostic gold nanomedical particles}

The present invention relates to a composition for treating autoimmune diseases and mitochondria using theragnostic gold nanomedical particles.

Diseases caused by immune hypersensitivity reactions are increasing worldwide, but the fundamental causes of the occurrence of these diseases have not been sufficiently identified. Currently, as a treatment method for diseases caused by an excessive immune response, various symptoms caused by the diseases are alleviated or reduced by administering an immunosuppressive agent alone or in combination.

Immunosuppressive agents refer to various substances used to reduce or block the ability of a host to produce antibodies against the action of an antigen (humoral immune response) or to induce a cellular immune response. These immunosuppressants can be usefully used not only in the field of organ transplantation, but also in autoimmune diseases such as lupus and rheumatoid arthritis, and skin hypersensitivity reactions such as atopy and allergy. An excellent immunosuppressive agent should be able to control the imbalance of the immune response, should be safe for the human body, and should have a low frequency of disease recurrence during long-term treatment.

Currently used immunosuppressants include cyclosporin A and FK506, which are compounds derived from natural products with complex chemical structures that are uneconomical due to the high cost in terms of raw material supply and long-term administration, which can cause various side effects. There is a risk that there is Therefore, there is an urgent need for the development of new immunosuppressants capable of economical production with low toxicity and induction of immune tolerance.

On the other hand, T cells are one of the cell groups that play a central role in the immune system as a biological defense system against various pathogens. T cells are produced in the human thymus and differentiate into T cells with unique characteristics through a series of differentiation processes. It is divided into helper cells (Th2). Among them, the main function of Th1 cells is involved in cell-mediated immunity, and Th2 cells are involved in humoral immunity.

Therefore, most of the immune diseases can be seen as being caused by an imbalance between these two immune cells. For example, when the activity of Th1 cells is abnormally increased, autoimmune diseases can occur, and the activity of Th2 cells is abnormally increased. It is known that immune diseases caused by hypersensitivity reactions occur.

On the other hand, according to recent research results on the differentiation of Th1 cells, as the existence of immunoregulatory T cells (Tregs), a new group capable of regulating the activity of Th1 cells, has been known, research on the treatment of immune diseases using them has emerged. , Treg cells have the property of controlling the inflammatory response by suppressing the function of abnormally activated immune cells, and many studies are being conducted to treat immune diseases through the action of increasing the activity of Treg cells.

In addition, there are Th17 cells as another group formed during the differentiation process of T cells other than Treg cells. It is known that Th17 cells are formed during the differentiation process of undifferentiated T cells through a process similar to that of Treg cells. That is, the differentiation of Treg cells and Th17 cells is commonly achieved in the presence of TGF-β, but IL-6 is not required for Treg cells, whereas IL-6 is present together with TGF-β for Th17 cells. differentiate in the circumstances. Also, differentiated Th17 cells are characterized by secreting IL-17.

It has been revealed that Th17 cells, unlike Treg cells, are involved in the forefront of the inflammatory response seen in immune diseases, maximizing the signal of the inflammatory response and accelerating the progression of the disease. Therefore, in the case of autoimmune diseases that are not controlled by Treg cells among autoimmune diseases, the development of a therapeutic agent for autoimmune diseases targeting inhibition of Th17 cell activity has been greatly highlighted.

On the other hand, there are signal transduction mechanisms closely related to cell death inside mitochondria, and if we can interpret and control these signals, it can be applied to disease treatment (Biochimica et Biophysica Acta, 2006; Cell, 2005; Trends Biochem Sci, 2005; Nature Med, 2005; Nature, 2005; J Clin Invest, 2005; Heart Lung Circ, 2005; J Nat Cancer Inst, 2005, Science, 2005). Mitochondrial dysfunction is not a single symptom or disease, but can appear as a variety of diseases in various organs in the human body, and the possibility of pathological and disease-specific treatments related to diseased mitochondria has been raised. It is a state. In particular, the increase in oxidative stress due to increased intracellular reactive oxygen species has recently been suggested as a fundamental cytological and molecular biological mechanism in cardiovascular and metabolic diseases as well as neurodegenerative diseases. The efficacy of antioxidant treatment is still controversial. Therefore, gene therapy as a micro-targeting therapy that can transplant intact mitochondria or regulate the expression of membrane and matrix proteins that can directly control mitochondrial function is a strategy with high potential as a permanent or semi-permanent treatment. can be

An object of the present invention is to provide a pharmaceutical composition for preventing or treating arthritis, comprising gold nano-particles as an active ingredient.

Another object of the present invention is to provide a food composition for preventing or improving arthritis, containing gold nano-particles as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating arthritis, comprising gold nano-particles as an active ingredient.

In addition, the present invention provides a food composition for preventing or improving arthritis, including gold nano-particles as an active ingredient.

It was confirmed that the gold nanoparticles of the present invention reduced the index and prevalence of arthritis and protected joint tissues in an animal model in which rheumatoid arthritis was induced. In addition, it was confirmed that mitochondrial activity, which is known to be decreased in the rheumatoid arthritis model, was increased, and expression of Th17 cells was suppressed. In addition, it was confirmed that the amount of inflammatory cytokines IL-1β, IL-17, IL-6 and TNF-α was reduced, and the amount of citrulinet vimentin specific IgG in serum was reduced, thereby confirming the therapeutic effect of arthritis, It can be usefully used in related industries.

1 is a diagram showing the results of UV-Vis Absorption analysis and SEM (scanning electron microscope) observation of the gold nanoparticles of the present invention (A: UV-Vis Absorption, B: SEM results).
FIG. 2 is a diagram illustrating arthritis score and incidence by treating rheumatoid arthritis-induced mice with gold nanoparticles (A: arthritis score confirmed, B: prevalence confirmed).
Figure 3 is a diagram showing the degree of joint damage by treating rheumatoid arthritis-induced mice with gold nanoparticles, and confirming the degree of joint damage by hematoxylin & eosin staining and safranin O staining (A: staining result, B: quantification of joint damage index)
FIG. 4 is a diagram illustrating the improvement of mitochondrial function of spleen cells by treating rheumatoid arthritis-induced mice with gold nanoparticles (A: confirming an increase in the amount of ATP; B: confirming an increase in the ability to synthesize ATP).
5 is a diagram confirming mitochondrial respiration in splenocytes by OCR assay by treating rheumatoid arthritis-induced mice with gold nanoparticles.
6 is a diagram illustrating the analysis of Th17 cell expression in splenocytes by flow cytometry analysis by treating rheumatoid arthritis-induced mice with gold nanoparticles (A: result of flow cytometry, B: quantification of expression level)
7 is a diagram illustrating the amount of inflammatory cytokines in a joint treated with gold nanoparticles in a mouse induced with rheumatoid arthritis by immunohistochemical staining (A: staining result, B: quantification of inflammatory cytokine expression).
8 is a diagram confirming the amount of citrulinet vimentin specific IgG in serum by treating a mouse with rheumatoid arthritis with gold nanoparticles.

The present invention provides a pharmaceutical composition for preventing or treating arthritis, comprising gold nano-particles as an active ingredient.

As used herein, the term "prevention" refers to any action that suppresses symptoms or delays the progression of a specific disease by administering the composition of the present invention.

The term "treatment" used in the present invention refers to all activities that improve or beneficially change the symptoms of a specific disease by administering the composition of the present invention.

"Nano-particle" of the present invention refers to fine particles whose particle size can be expressed in nanometer units.

The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. As long as the adjuvant is known in the art, any one may be used without limitation, but, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase the effect.

The pharmaceutical composition according to the present invention may be prepared in the form of incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers usable in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories or sterile injection solutions according to conventional methods, respectively. .

When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, and gelatin in addition to active ingredients. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. can Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for suppositories, witepsol, tween 61, cacao paper, laurin paper, glycerogelatin, and the like may be used.

The pharmaceutical composition according to the present invention can be administered to a subject by various routes. All modes of administration are contemplated, eg oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The dosage of the pharmaceutical composition according to the present invention is selected in consideration of the age, weight, sex, and physical condition of the subject. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be variously selected according to the subject, and is preferably included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg/ml. If the concentration is less than 0.01 μg/ml, pharmacological activity may not appear, and if the concentration exceeds 5,000 μg/ml, toxicity to the human body may be exhibited.

According to one embodiment of the present invention, the gold nanoparticles may have a particle size of 20 to 40 nm, preferably 25 to 35 nm, but are not limited thereto.

According to one embodiment of the present invention, the composition may reduce arthritis score and incidence.

According to one embodiment of the present invention, the composition may be to increase the function of mitochondria, and the increase in the function of mitochondria, the amount of ATP (ATP contents), ATP synthesis capacity (ATP synthesis) and the amount of respiration of the mitochondria may be an increase.

According to one embodiment of the present invention, the composition may inhibit the expression of Th17 cells.

According to one embodiment of the present invention, the composition, may be to reduce the amount of inflammatory cytokines, the inflammatory cytokines IL-1β (interleukin 1 beta), IL-17 (interleukin 17), IL-6 It may be selected from the group consisting of (interleukin 6) and TNF-α (tumor necrosis factor-α), but is not limited thereto.

According to one embodiment of the present invention, the composition may reduce the amount of citrulinet vimentin specific IgG in serum.

According to one embodiment of the present invention, the arthritis may be rheumatoid arthritis or osteoarthritis, preferably rheumatoid arthritis, but is not limited thereto.

In addition, the present invention provides a food composition for preventing or improving arthritis, including gold nano-particles as an active ingredient.

As used herein, the term "improvement" refers to any action that at least reduces the severity of a parameter related to the condition being treated, for example, a symptom.

In addition to containing the active ingredient of the present invention, the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional food compositions.

Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agents described above, natural flavoring agents (thaumatin), stevia extracts (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. The food composition of the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements, etc. there is

In addition, the food composition, in addition to the active ingredient extract, various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, Alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like may be contained. In addition, the food composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages.

The functional food composition of the present invention may be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of preventing or treating arthritis. In the present invention, 'health functional food composition' refers to a food manufactured and processed using raw materials or ingredients having useful functionality for the human body according to Health Functional Food Act No. 6727, and the structure and function of the human body It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological functions. The health functional food of the present invention may contain ordinary food additives, and the suitability as a food additive is determined according to the general rules of the Food Additive Code and General Test Methods approved by the Food and Drug Administration, unless otherwise specified. It is judged according to standards and standards. Examples of the items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations. For example, a health functional food in the form of a tablet is obtained by granulating a mixture obtained by mixing the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives in a conventional manner, and then adding a lubricant or the like to compression molding, or as described above. The mixture can be directly compression molded. In addition, the health functional food in the form of a tablet may contain a flavoring agent and the like as needed. Among health functional foods in the form of capsules, hard capsules can be prepared by filling a mixture in which the active ingredient of the present invention is mixed with additives such as excipients in a normal hard capsule. It can be prepared by filling the mixture mixed with gelatin in a capsule base. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. The health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention mixed with an excipient, a binder, a disintegrant, etc. by a conventionally known method, and can be coated with sucrose or other coating agent if necessary, Alternatively, the surface may be coated with a material such as starch or talc. Health functional food in the form of granules can be prepared in granular form by a conventionally known method of mixing the active ingredient of the present invention with excipients, binders, disintegrants, etc., and, if necessary, flavoring agents, flavoring agents, etc. can

Hereinafter, the present invention will be described in more detail by examples. These examples are merely for explaining the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited to these examples.

<Preparation Example 1> Preparation of gold nano-particle

The present inventors prepared gold nano-particles (Gold-NP) in order to confirm whether they are effective for arthritis. Specifically, it was synthesized using the seed mediated growth method. To prepare spherical gold nanoparticles with a size of 17 nm, 3 ml of citric acid (Citrate, 0.01 g) was added to 100 ml of gold precursor (HAuCl ₄ , 0.01 wt%) at 95 ° C. /ml) was added and reacted for 20 minutes. Then, for the growth of additional particles, 10 ml of synthesized 17 nm spherical gold nanoparticles and 0.833 ml of the gold precursor at a concentration of 0.01 g/ml were added to 90 ml of deionized water (DI water). . Thereafter, 1 ml of hydroxylamine hydrochloride was added at a concentration of 0.2 M and reacted for 20 minutes. After that, the size of the gold nanoparticles was confirmed by UV-Vis Absorption and scanning electron microscope (SEM).

As a result, as shown in FIG. 1, it was confirmed that the gold nanoparticles of the present invention absorb wavelengths of 400 to 700 nm (FIG. 1A) and have a size of 31.5 ± 3.2 nm through SEM photo analysis (FIG. 1B). ).

<Example 1> Confirmation of effect of gold nanoparticles in rheumatoid arthritis animal model

In order to confirm the effect of the gold nanoparticles of the present invention on rheumatoid arthritis, a rheumatoid arthritis animal model was prepared. Specifically, through intradermal injection into the tail of 7-week-old male DBA mice, type 2 collagen was dissolved in 0.1 N acetic acid to a concentration of 4 mg/ml, and the same amount of Complete Freud's adjuvant (CFA , Chondrex) was first injected. Two weeks later, rheumatoid arthritis was induced by injecting type 2 collagen and imcomplete Freud's adjuvant (IFA, Chondrex) in the same manner. Thereafter, the gold nanoparticles of Preparation Example 1 were diluted in distilled water at a concentration of 10 mg/kg and intraperitoneally administered twice a week (Gold-NP group). Then, the arthritis score and incidence were evaluated twice a week. As a control group, a vehicle group in which rheumatoid arthritis was induced and physiological saline was injected was used, and the scores and criteria according to the arthritis evaluation are as follows.

0 point: There is no deficiency or swelling.

1 point: Mild swelling and redness localized to the foot or ankle joint

2 points: Mild swelling and redness from the ankle joint to the metatarsal

3 points: Moderate swelling and redness from the ankle joint to the tarsal bone

4 points: swelling and redness from the ankle to the entire leg

As a result, compared to the Vehicle group, it was confirmed that the arthritis index (Fig. 2A) and prevalence (Fig. 2B) were significantly reduced in the Gold-NP group, indicating that the gold nanoparticles of the present invention inhibit the progression of rheumatoid arthritis. confirmed that

<Example 2> Confirmation of joint protection effect of gold nanoparticles

The mice of each group of Example 1 were humanely sacrificed at the end of the experiment, and joint tissues were separated and fixed. After that, the joint tissue was prepared as a section, and the degree of damage to the joint tissue was evaluated by hematoxylin & eosin (H&E) staining and safranine O staining. Inflammation score, bone damage (bone damage) damage) and cartilage damage index.

As a result, as shown in FIG. 3, it was confirmed that, compared to the Vehicle group, the inflammation score, bone damage, and cartilage damage scores were significantly reduced in the Gold-NP group.

<Example 3> Confirmation of mitochondrial function improvement of gold nanoparticles

<3-1> Confirmation of ATP amount and ATP synthesis ability improvement

Since mitochondrial function has been reported to be reduced in the rheumatoid arthritis model, it was confirmed that the gold nanoparticles of the present invention improve mitochondrial function in rheumatoid arthritis. Specifically, the spleen was removed from the mouse sacrificed in Example 2, and ATP contents and ATP synthesis were confirmed in order to evaluate mitochondrial function improvement of the gold nanoparticles in the splenocytes. After reacting the gold nanoparticles of the isolated splenocytes for 24 hours, the ATP measurement experiment was conducted using the Perkin Elmer ATP Lite Luminescence Assay kit. In the case of ATP synthesis ability, the cells were stimulated with 1 mM ADP and reacted for 45 minutes, and then the amount of ATP was measured using a kit.

As a result, as shown in FIG. 4 , compared to the Vehicle group, in the Gold-NP group, it was confirmed that the amount of ATP and the synthesis of ATP increased in the splenocytes, indicating that mitochondrial function was improved.

<3-2> Confirmation of increased mitochondrial respiration

The spleen was removed from the mouse sacrificed in Example 2, and mitochondrial respiration was evaluated using OCR assay in order to evaluate mitochondrial function improvement of gold nanoparticles in spleen cells. The OCR assay was measured using the XF seahorse equipment, 1x10^6 cells of splenocytes from sacrificed mice were put into an OCR plate, and mitochondrial electron transport inhibitors (Oligomycin 7mM, FCCP 3mM, Rotenone 10uM, Antimycin-A 10uM) were applied to OCR. put on plate Equipment use was conducted through the XF seahorse program.

As a result, as shown in FIG. 5 , compared to the Vehicle group, in the Gold-NP group, it was confirmed that the amount of mitochondrial respiration in spleen cells was increased, and mitochondrial function was improved.

<Example 4> Confirmation of regulation of immune cell expression by gold nanoparticles

In order to confirm whether the gold nanoparticles of the present invention inhibit the expression of Th17 cells, which are the main etiologic cells of rheumatoid arthritis, spleens were obtained from the sacrificed mice of Example 2, and IL-17 positive cells in the spleen cells were analyzed by flow cytometry analyzed.

As a result, it was confirmed that the expression of Th17 cells was significantly decreased in the Gold-NP group compared to the Vehicle group (FIG. 6).

<Example 5> Confirmation of suppression of inflammatory cytokines by gold nanoparticles

After preparing the intestinal tissue obtained in Example 2 as a paraffin block, cutting it to prepare a section, inflammatory cytokines IL-1β (interleukin 1β), IL-17 (interleukin 17), IL-6 (interleukin 6) ) and expression of TNF-α (tumor necrosis factor-α) was confirmed through immunohistochemical staining.

As a result, as shown in FIG. 7, it was confirmed that the expression of inflammatory cytokines IL-1β, IL-17, IL-6, and TNF-α was significantly decreased in the Gold-NP group compared to the Vehicle group. .

<Example 6> Confirmation of suppression of Citrulinet vimentin specific IgG expression

It was intended to confirm whether the gold nanoparticles of the present invention can inhibit citrulinet vimentin specific IgG, an abnormal vimentin that increases in a rheumatoid arthritis model. Specifically, whole blood of the mouse sacrificed in Example 2 was obtained, and the expression of citrulinet vimentin specific IgG was confirmed through serum analysis from the obtained whole blood. An ELISA plate was coated with 5ug of Vimentin peptide for 2 hours, and mouse serum was added thereto. After that, IgG HRP was added and reacted for 2 hours, and color development was measured at an absorption wavelength of 450 nm.

As a result, as shown in FIG. 8, compared to the Vehicle group, the Gold-NP group did not show a significant difference in the expression of vimentin specific IgG, but it was confirmed that the expression of citrulinet vimentin specific IgG was significantly reduced. It was confirmed that the gold nanoparticles of , without reducing the expression of total vimentin, regulate the expression of abnormal vimentin in rheumatoid arthritis.

Therefore, it was confirmed that the gold nanoparticles of the present invention reduce the index and prevalence of arthritis and protect joint tissues in an animal model in which rheumatoid arthritis is induced. In addition, it was confirmed that mitochondrial activity, which is known to be decreased in the rheumatoid arthritis model, was increased, and expression of Th17 cells was suppressed. In addition, it was confirmed that the amounts of inflammatory cytokines IL-1β, IL-17, IL-6, and TNF-α were reduced, and the amount of citrulinet vimentin specific IgG in serum was reduced, thereby confirming the therapeutic effect of arthritis.

Claims (13)

A pharmaceutical composition for preventing or treating arthritis, comprising gold nano-particles as an active ingredient. According to claim 1,
The gold nanoparticles having a particle size of 20 to 40 nm, a pharmaceutical composition for preventing or treating arthritis. According to claim 1,
The composition is to reduce the arthritis index (arthritis score) and prevalence (indicence), a pharmaceutical composition for preventing or treating arthritis. According to claim 1,
The composition, to increase the function of mitochondria, a pharmaceutical composition for the prevention or treatment of arthritis. According to claim 4,
The increase in mitochondrial function is to increase the amount of ATP (ATP contents), a pharmaceutical composition for preventing or treating arthritis. According to claim 4,
The increase in mitochondrial function is to increase ATP synthesis, a pharmaceutical composition for preventing or treating arthritis. According to claim 4,
The increase in mitochondrial function, to increase the amount of respiration of mitochondria, a pharmaceutical composition for preventing or treating arthritis. According to claim 1,
The composition inhibits the expression of Th17 cells, a pharmaceutical composition for preventing or treating arthritis. According to claim 1,
The composition is to reduce the amount of inflammatory cytokines, a pharmaceutical composition for the prevention or treatment of arthritis. According to claim 9,
The inflammatory cytokine is one selected from the group consisting of interleukin 1 beta (IL-1β), interleukin 17 (IL-17), interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) of arthritis A pharmaceutical composition for prevention or treatment. According to claim 1,
Wherein the composition reduces the amount of citrulinet vimentin specific IgG in serum, a pharmaceutical composition for preventing or treating arthritis. According to claim 1,
The arthritis is, rheumatoid arthritis (Rheumatoid Arthritis) or osteoarthritis (osteoarthritis), a pharmaceutical composition for the prevention or treatment of arthritis. A food composition for preventing or improving arthritis, comprising gold nano-particles as an active ingredient.

Images